Cardiff Oncology (CRDF) News Today $2.41 -0.03 (-1.23%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$2.46 +0.04 (+1.87%) As of 06:15 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRDF Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Cardiff Oncology (NASDAQ:CRDF) Price Target Lowered to $10.00 at HC Wainwright5 hours ago | americanbankingnews.comHC Wainwright Lowers Cardiff Oncology (NASDAQ:CRDF) Price Target to $10.00August 7 at 8:38 AM | marketbeat.comBlair William & Co. IL Buys 1,469,249 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF)August 7 at 4:15 AM | marketbeat.comCardiff Oncology (CRDF) Projected to Post Earnings on ThursdayAugust 7 at 2:51 AM | marketbeat.comCardiff Oncology, Inc. (NASDAQ:CRDF) Receives $11.70 Average Price Target from AnalystsAugust 5 at 2:09 AM | americanbankingnews.comCardiff Oncology, Inc. (NASDAQ:CRDF) Given Average Rating of "Moderate Buy" by BrokeragesAugust 3, 2025 | marketbeat.comWilliam Blair Boosts Earnings Estimates for Cardiff OncologyAugust 3, 2025 | americanbankingnews.comWilliam Blair Has Optimistic Outlook of CRDF Q3 EarningsAugust 2, 2025 | marketbeat.comGary W. Pace Purchases 15,000 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) StockAugust 1, 2025 | marketbeat.comInsider Buying: Cardiff Oncology, Inc. (NASDAQ:CRDF) Director Acquires 275,000 Shares of StockAugust 1, 2025 | marketbeat.comGary W. Pace Buys 15,000 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) StockAugust 1, 2025 | insidertrades.comCardiff Oncology Target of Unusually High Options Trading (NASDAQ:CRDF)July 31, 2025 | marketbeat.comCardiff Oncology Insiders Land Bargain With Gains Of US$244kJuly 31, 2025 | finance.yahoo.comCardiff Oncology Reports Second Quarter 2025 Results and Provides Business UpdateJuly 31, 2025 | finance.yahoo.comCardiff Oncology (CRDF) Q2 Loss Down 19%July 30, 2025 | fool.comCardiff Oncology (NASDAQ:CRDF) Posts Quarterly Earnings Results, Misses Expectations By $0.02 EPSJuly 30, 2025 | marketbeat.comWhy Is Cardiff Oncology Stock Trading Lower After Colorectal Cancer Data?July 30, 2025 | benzinga.comCardiff Oncology: Data Update Resolves Some SignalsJuly 30, 2025 | seekingalpha.comCardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004)July 29, 2025 | globenewswire.com96,208 Shares in Cardiff Oncology, Inc. (NASDAQ:CRDF) Purchased by Dauntless Investment Group LLCJuly 29, 2025 | marketbeat.comCardiff Oncology: Volatility Afoot With Onvansertib Update Near-TermJuly 18, 2025 | seekingalpha.comLadenburg Thalmann Initiates Coverage of Cardiff Oncology (CRDF) with Buy RecommendationJuly 9, 2025 | msn.comCardiff Oncology, Inc. (NASDAQ:CRDF) Receives Consensus Rating of "Moderate Buy" from BrokeragesJuly 8, 2025 | marketbeat.comCardiff Oncology (NASDAQ:CRDF) Coverage Initiated by Analysts at LADENBURG THALM/SH SHJuly 8, 2025 | marketbeat.comWhile institutions invested in Cardiff Oncology, Inc. (NASDAQ:CRDF) benefited from last week's 16% gain, retail investors stood to gain the mostJuly 3, 2025 | finance.yahoo.comCRDF - Cardiff Oncology Inc Ownership - MorningstarJuly 2, 2025 | morningstar.comMCardiff Oncology: Delayed Trial Data Update Unnerves Investors But Gives Bulls A Final Buy Low OpportunityJune 27, 2025 | seekingalpha.comCardiff Oncology, Inc. (CRDF) - Yahoo FinanceJune 26, 2025 | finance.yahoo.comCardiff Oncology (NASDAQ:CRDF) Coverage Initiated by Analysts at Jefferies Financial GroupJune 24, 2025 | marketbeat.comCardiff Oncology to share CRDF-004 trial data on July 29June 19, 2025 | finance.yahoo.comCardiff selloff brings attractive entry point, says H.C. WainwrightJune 19, 2025 | finance.yahoo.comCardiff Oncology Appoints Roger Sidhu, MD as Chief Medical Officer and Announces Upcoming Clinical Data Update for Onvansertib in mCRC TrialJune 19, 2025 | nasdaq.comCardiff Oncology (NASDAQ:CRDF) Given "Outperform" Rating at William BlairJune 18, 2025 | marketbeat.comCardiff Oncology Names Roger Sidhu as Medical ChiefJune 17, 2025 | marketwatch.comCardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRCJune 17, 2025 | globenewswire.comTwo Sigma Investments LP Trims Stake in Cardiff Oncology, Inc. (NASDAQ:CRDF)June 10, 2025 | marketbeat.comTwo Sigma Advisers LP Trims Stake in Cardiff Oncology, Inc. (NASDAQ:CRDF)June 9, 2025 | marketbeat.comYarbrough Capital LLC Makes New $277,000 Investment in Cardiff Oncology, Inc. (NASDAQ:CRDF)June 8, 2025 | marketbeat.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Cardiff Oncology (CRDF) and Theravance Biopharma (TBPH)June 4, 2025 | theglobeandmail.comCardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented ...June 4, 2025 | morningstar.comMCardiff Oncology Reports 40% Objective Response Rate in Phase 1b Trial of Onvansertib and Paclitaxel for Metastatic Triple-Negative Breast CancerJune 4, 2025 | nasdaq.comNuveen Asset Management LLC Acquires 248,850 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF)June 3, 2025 | marketbeat.comMillennium Management LLC Buys 288,259 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF)June 3, 2025 | marketbeat.comCardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025June 2, 2025 | globenewswire.comSA Asks: Which oncology companies are attractive M&A targets?May 30, 2025 | msn.comAWM Investment Company Inc. Acquires New Stake in Cardiff Oncology, Inc. (NASDAQ:CRDF)May 23, 2025 | marketbeat.comPoint72 Asset Management L.P. Buys New Stake in Cardiff Oncology, Inc. (NASDAQ:CRDF)May 23, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Takes $607,000 Position in Cardiff Oncology, Inc. (NASDAQ:CRDF)May 20, 2025 | marketbeat.comOrbimed Advisors LLC Makes New Investment in Cardiff Oncology, Inc. (NASDAQ:CRDF)May 15, 2025 | marketbeat.comCardiff Oncology: Buying The First-Line Onvansertib StrategyMay 14, 2025 | seekingalpha.com Get Cardiff Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for CRDF and its competitors with MarketBeat's FREE daily newsletter. Email Address CRDF Media Mentions By Week CRDF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CRDF News Sentiment▼0.910.39▲Average Medical News Sentiment CRDF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CRDF Articles This Week▼142▲CRDF Articles Average Week Get Cardiff Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for CRDF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies VIR News Today AMLX News Today DAWN News Today DNTH News Today KALV News Today MAZE News Today AVBP News Today MNMD News Today ABUS News Today AUTL News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CRDF) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiff Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cardiff Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
